Residency · Residency · Nephrology

Hyponatremia - Diagnostic and Therapeutic Approach

Introduction

Hyponatremia, defined as a serum sodium concentration below 135 mEq/L, is the most common electrolyte disorder encountered in hospitalized patients, with a prevalence of approximately 15 to 30 percent depending on the threshold used and the patient population studied. Even mild hyponatremia in the range of 130 to 134 mEq/L is not benign: it is associated with increased falls, cognitive impairment, osteoporosis, fractures, and mortality. Severe hyponatremia below 120 mEq/L can produce life-threatening cerebral edema, seizures, coma, and death from brain herniation. The central challenge in managing hyponatremia lies in balancing two competing risks: the immediate danger of hyponatremia-induced brain injury against the iatrogenic risk of osmotic demyelination syndrome from overly rapid correction of chronic hyponatremia. Mastery of the diagnostic approach, understanding of cerebral adaptation, and meticulous attention to correction rates are the pillars of safe and effective management.

Classification

By Serum Osmolality

The first step in evaluating hyponatremia is to determine the serum osmolality, which classifies the disorder into one of three categories. Hypotonic hyponatremia, defined by a plasma osmolality below 275 mOsm/kg, represents true hyponatremia with an excess of water relative to sodium and constitutes the vast majority of clinical hyponatremia. Isotonic hyponatremia, with a plasma osmolality in the normal range of 275 to 295 mOsm/kg, is pseudohyponatremia caused by severe hyperlipidemia or hyperproteinemia. In these conditions, the aqueous phase of plasma (where sodium resides) has a normal sodium concentration, but the measured sodium is artifactually low because lipid or protein displaces a portion of the plasma volume. This artifact affects indirect ion-selective electrode methods used in most central laboratory analyzers but does not affect direct ion-selective electrode measurements or blood gas analyzers. Hypertonic hyponatremia, with a plasma osmolality exceeding 295 mOsm/kg, is translocational hyponatremia caused by effective osmoles in the extracellular fluid that draw water from the intracellular compartment, diluting the plasma sodium concentration. The most common cause is hyperglycemia, for which the corrected sodium is calculated by adding 1.6 mEq/L to the measured sodium for every 100 mg/dL increment in glucose above 100, with some authorities using a correction factor of 2.4 for glucose levels above 400 mg/dL. Mannitol, sorbitol, and glycine (as in TURP syndrome) are additional causes of hypertonic hyponatremia.

By Volume Status (Hypotonic Hyponatremia)

Once hypotonic hyponatremia is confirmed, clinical assessment of volume status guides further differential diagnosis. Hypovolemic hyponatremia is characterized by total body sodium depletion accompanied by proportionally greater water depletion, or more commonly, ongoing water intake that exceeds the diminished water excretory capacity induced by hypovolemia-stimulated ADH release. The urine sodium distinguishes renal from extrarenal losses: a urine sodium exceeding 20 mEq/L indicates renal sodium loss from diuretics, mineralocorticoid deficiency, salt-wasting nephropathy, cerebral salt wasting, or osmotic diuresis, while a urine sodium below 20 mEq/L indicates extrarenal losses from diarrhea, vomiting, third-spacing, burns, or pancreatitis.

Euvolemic hyponatremia is the most common category in clinical practice and is defined by a normal or near-normal total body sodium with an excess of total body water. The syndrome of inappropriate antidiuresis (SIADH) is the most common cause. Other etiologies include severe hypothyroidism (myxedema), adrenal insufficiency (in which cortisol deficiency stimulates ADH release through a glucocorticoid-dependent mechanism), primary polydipsia (in which water intake exceeds the renal diluting capacity, typically requiring ingestion of more than 15 to 20 liters per day), reset osmostat (in which the threshold for ADH release is lowered, as seen in pregnancy and chronic illness), and beer potomania or the tea-and-toast syndrome, in which a very low daily solute intake limits the kidney's capacity to excrete free water despite normal diluting mechanisms.

Hypervolemic hyponatremia occurs in edematous states where total body sodium is increased but total body water is increased proportionally more, resulting in a diluted serum sodium. Congestive heart failure, hepatic cirrhosis, and nephrotic syndrome produce this pattern through reduced effective arterial blood volume, which stimulates ADH release despite total body volume overload. Advanced chronic kidney disease and end-stage renal disease also cause hypervolemic hyponatremia through impaired free water excretion.

<image>Diagnostic algorithm for hyponatremia. Start with serum sodium <135 mEq/L. Step 1: Check serum osmolality. If >295 (hypertonic): calculate corrected sodium for glucose, consider mannitol. If 275-295 (isotonic): pseudohyponatremia, check lipids and protein, use direct ISE or blood gas. If <275 (hypotonic): proceed to step 2. Step 2: Assess volume status (clinical exam: JVP, skin turgor, orthostatics, edema, mucous membranes). Branch into hypovolemic, euvolemic, and hypervolemic. Step 3: Check urine osmolality and urine sodium. For hypovolemic: UNa >20 = renal loss (diuretics, adrenal insufficiency, cerebral salt wasting); UNa <20 = extrarenal loss (GI, skin). For euvolemic: Uosm >100 with UNa >30 = SIADH; Uosm <100 = primary polydipsia, beer potomania. For hypervolemic: UNa <20 = CHF, cirrhosis, nephrotic syndrome; UNa >20 = CKD/ESRD. Include a checklist of SIADH diagnostic criteria in a side box.</image>

SIADH (Syndrome of Inappropriate Antidiuresis)

Diagnostic Criteria (Bartter and Schwartz)

The diagnosis of SIADH requires fulfillment of the classic criteria originally described by Bartter and Schwartz. The serum osmolality must be below 275 mOsm/kg. The urine osmolality must be inappropriately concentrated, exceeding 100 mOsm/kg and typically well above 300 mOsm/kg, when it should be maximally dilute in the setting of hypotonic hyponatremia. The urine sodium must be greater than 30 mEq/L with normal sodium intake, reflecting appropriate renal sodium handling in the absence of volume depletion. The patient must be clinically euvolemic, without edema or signs of orthostatic hypotension. Normal thyroid and adrenal function must be documented, as hypothyroidism and adrenal insufficiency can produce an identical biochemical picture. There should be no recent diuretic use, which confounds urine electrolyte interpretation.

Etiologies

The causes of SIADH are diverse and span multiple organ systems. Central nervous system disorders including stroke, intracranial hemorrhage, meningitis, encephalitis, traumatic brain injury, and Guillain-Barre syndrome can all stimulate inappropriate ADH release from the hypothalamus. Pulmonary disorders, including pneumonia, tuberculosis, lung abscess, chronic obstructive pulmonary disease, positive pressure ventilation, and primary lung malignancies, are common causes. Malignancies, most classically small cell lung cancer through ectopic ADH production, as well as head and neck cancers, lymphoma, and mesothelioma, can produce SIADH. Among drugs, selective serotonin reuptake inhibitors are the most common pharmacologic cause; other offending agents include carbamazepine and oxcarbazepine, cyclophosphamide, vincristine, ecstasy (MDMA), desmopressin, opioids, and oxytocin. Pain and nausea are potent physiologic stimuli for ADH release and should always be considered as contributors. Post-surgical hyponatremia, hereditary causes (gain-of-function V2 receptor mutations causing nephrogenic SIAD), and idiopathic SIADH in elderly patients round out the differential.

Cerebral Adaptation to Hyponatremia

Acute Hyponatremia (<48 hours)

When serum sodium falls rapidly, the resulting decrease in plasma osmolality creates an osmotic gradient that drives water into brain cells, causing cerebral edema. The brain initiates an adaptive response within hours, extruding intracellular electrolytes, primarily sodium, potassium, and chloride, through ion channels to reduce intracellular osmolality and restore cell volume toward normal. If the rate of sodium decline outpaces this adaptation, the resulting increase in intracranial pressure can progress to uncal herniation and death. Acute hyponatremia is most dangerous in specific clinical scenarios: post-operative patients receiving hypotonic intravenous fluids, psychogenic polydipsia with massive water intake, MDMA (ecstasy) ingestion, and exercise-associated hyponatremia in marathon runners, where non-osmotic ADH release combines with excessive hypotonic fluid intake.

Chronic Hyponatremia (>48 hours)

Over 24 to 48 hours, the brain deploys a second adaptive mechanism: extrusion of organic osmolytes, including glutamate, taurine, myo-inositol, and glycerophosphocholine, from brain cells. This process restores brain volume toward normal despite the persistently low serum sodium, resulting in a brain that is "adapted" to the hypo-osmolar state. While this adaptation protects against cerebral edema, it renders the brain exquisitely vulnerable to injury from overly rapid correction, because the organic osmolytes cannot be replenished quickly.

Osmotic Demyelination Syndrome (ODS)

Osmotic demyelination syndrome, formerly known as central pontine myelinolysis (though extrapontine structures including the basal ganglia, thalamus, and cerebellum can also be affected), is the devastating consequence of overly rapid sodium correction in a chronically adapted brain. When sodium is raised too quickly, the resulting increase in extracellular osmolality draws water out of brain cells that have depleted their organic osmolytes and cannot compensate. The resulting oligodendrocyte dehydration and shrinkage triggers demyelination, particularly in areas of close gray-white matter apposition such as the central pons.

Risk factors for ODS include a correction rate exceeding 8 to 10 mEq/L in any 24-hour period or exceeding 18 mEq/L in 48 hours, chronic hyponatremia of more than 48 hours' duration, severe hyponatremia with sodium below 120 mEq/L, concurrent hypokalemia, malnutrition, liver disease, and alcoholism. Clinical manifestations are characteristically delayed, appearing 2 to 6 days after the correction episode, and include pseudobulbar palsy, dysarthria, dysphagia, quadriparesis, locked-in syndrome, altered mental status, and seizures. MRI demonstrates T2 and FLAIR hyperintensity in the pons and affected extrapontine structures, though MRI findings may lag behind clinical symptoms by 1 to 2 weeks. There is no proven treatment for established ODS; prevention through meticulous rate control is paramount. If overcorrection is detected, the sodium should be actively re-lowered using desmopressin and dextrose 5 percent in water infusion.

Treatment

Emergency Treatment (Symptomatic Acute Hyponatremia)

When hyponatremia presents with severe neurologic symptoms including seizures, altered mental status, or respiratory arrest, the immediate priority is to reverse cerebral edema. Hypertonic saline (3 percent sodium chloride) is administered as a 100 mL intravenous bolus over 10 minutes, which can be repeated up to two additional times if symptoms persist. The goal is to raise the serum sodium by 4 to 6 mEq/L within the first 1 to 2 hours, which is typically sufficient to reduce intracranial pressure and halt brain herniation. In this acute, symptomatic scenario, the risk of ongoing brain herniation from hyponatremia far exceeds the risk of ODS, and treatment should not be delayed. Once the patient is stabilized and the immediate neurologic emergency is resolved, the rate of correction should be slowed to comply with safe limits for the remainder of the 24-hour period.

Correction Rate Limits

For chronic hyponatremia, the maximum correction rate is 8 mEq/L in any 24-hour period. Some experts advocate an even more conservative limit of 6 mEq/L per 24 hours in patients at particularly high risk for ODS, including those with liver disease, alcoholism, malnutrition, hypokalemia, or a starting sodium below 105 mEq/L. Over 48 hours, correction should not exceed 16 mEq/L. Serum sodium should be monitored every 4 to 6 hours during active treatment. If overcorrection is detected, prompt intervention with dextrose 5 percent in water infusion at 3 to 6 mL/kg/hr combined with desmopressin (DDAVP) 2 to 4 mcg intravenously or subcutaneously will re-lower the sodium and prevent ODS.

Desmopressin Clamp Strategy

The desmopressin clamp is an increasingly utilized strategy that provides precise control over the rate of sodium correction. By administering DDAVP 2 mcg intravenously or subcutaneously every 6 to 8 hours, the clinician eliminates the kidney's ability to generate free water diuresis (aquaresis), effectively "clamping" urine output to a concentrated, low-volume state. This removes the unpredictability of the kidney's response and allows sodium to be raised in a controlled, measured fashion with concurrent 3 percent saline infusion. The desmopressin clamp is particularly valuable in clinical scenarios where sudden suppression of ADH creates a high risk of overly rapid correction: hypovolemic hyponatremia treated with volume resuscitation (where restoring effective arterial blood volume abruptly suppresses ADH, causing massive aquaresis), ethanol cessation, and glucocorticoid replacement in newly diagnosed adrenal insufficiency.

Treatment by Etiology

Hypovolemic Hyponatremia

The treatment of hypovolemic hyponatremia is volume resuscitation with isotonic saline (0.9 percent sodium chloride). While this may seem counterintuitive, the saline corrects the volume deficit, restores effective arterial blood volume, and removes the hypovolemic stimulus for ADH release. However, this is precisely the scenario that carries the highest risk of overcorrection: once volume is restored and ADH is suppressed, the kidneys may excrete large volumes of dilute urine in a rapid aquaresis, causing the serum sodium to rise precipitously. Serum sodium must be monitored every 2 to 4 hours during resuscitation, and a proactive desmopressin clamp is recommended in severe cases to prevent this dangerous overcorrection.

SIADH

The treatment of SIADH is multifaceted and escalated according to severity and response. Fluid restriction to 800 to 1000 mL per day is the first-line intervention and is effective in mild cases. However, predictors of fluid restriction failure should be assessed: if the urine osmolality to plasma osmolality ratio exceeds 1, or if the sum of urine sodium and urine potassium exceeds the plasma sodium (the Furst formula, indicating that the kidney is generating electrolyte-free water-negative urine), fluid restriction alone will be insufficient.

For patients who fail fluid restriction, salt tablets at 3 to 9 grams of sodium chloride per day combined with a loop diuretic such as furosemide can enhance free water excretion by increasing the solute load delivered to the kidney while the loop diuretic impairs urine concentrating ability. Oral urea at 15 to 30 grams per day is a first-line therapy in Europe and is gaining acceptance in the United States; it promotes free water excretion through osmotic diuresis and has supporting evidence from the FRACAS study.

Tolvaptan (Samsca) is a selective vasopressin V2 receptor antagonist that promotes aquaresis by blocking ADH-mediated water reabsorption in the collecting duct. It is highly effective for raising serum sodium in SIADH, starting at 15 mg daily and titrable to 30 to 60 mg. Initiation must occur in the hospital setting with close sodium monitoring due to the risk of overcorrection; if sodium rises more than 6 mEq/L in the first 12 hours, the next dose should be held. An FDA black box warning for hepatotoxicity limits its use to 30 days unless the risk-benefit is carefully reassessed. Tolvaptan is contraindicated in hypovolemic hyponatremia and liver disease based on the SALT-1 and SALT-2 trials. Conivaptan is a combined V1a/V2 receptor antagonist available only in intravenous formulation, limiting its use to the hospital setting.

Hypervolemic Hyponatremia

Management of hypervolemic hyponatremia targets both fluid and sodium restriction. Loop diuretics increase free water clearance by impairing urine concentrating ability and are the primary pharmacologic tool. Treatment of the underlying disease is essential: optimization of heart failure therapy with SGLT2 inhibitors and ARNI, management of cirrhosis with consideration of TIPS or liver transplantation, and treatment of nephrotic syndrome. Tolvaptan has a limited role in hypervolemic hyponatremia; while it improves serum sodium, the EVEREST trial demonstrated no mortality benefit in heart failure patients.

<image>Treatment approach flowchart for hyponatremia based on severity and chronicity. Start with symptom assessment: (1) Severe symptoms (seizures, coma, respiratory arrest) → 3% NaCl 100 mL bolus x 1-3 over 10 minutes each, target 4-6 mEq/L rise in 1-2 hours, then slow to ≤8 mEq/L/24 hours. (2) Moderate symptoms (confusion, headache, nausea) → 3% NaCl continuous infusion, target ≤8 mEq/L/24 hours. (3) Mild/asymptomatic → treat underlying cause: hypovolemic (isotonic saline with caution for overcorrection, consider DDAVP clamp), euvolemic/SIADH (fluid restriction, salt tabs + loop diuretic, oral urea, tolvaptan if refractory), hypervolemic (fluid and sodium restriction, diuretics). Show a monitoring panel: check sodium every 2-4 hours during active treatment, every 4-6 hours once stable. Include overcorrection rescue protocol: if sodium rises >8 mEq/L in 24 hours, give DDAVP 2 mcg IV + D5W to re-lower sodium.</image>

Special Populations

Exercise-Associated Hyponatremia

Exercise-associated hyponatremia is a potentially fatal condition that occurs predominantly in marathon runners and ultra-endurance athletes. The mechanism combines excessive hypotonic fluid intake during prolonged exercise with non-osmotic ADH release stimulated by pain, nausea, stress, and volume contraction. The resulting hyponatremia can produce fatal cerebral edema in otherwise young, healthy individuals. Symptomatic cases require treatment with hypertonic saline, while mild cases respond to fluid restriction. Prevention centers on the simple principle of drinking to thirst rather than adhering to a predetermined hydration schedule.

Post-Operative Hyponatremia

Post-operative hyponatremia results from the combination of hypotonic intravenous fluid administration and non-osmotic ADH stimulation from surgical stress, pain, nausea, and anesthetic agents. This scenario is particularly dangerous in young women and children, in whom estrogen may impair the brain's adaptive capacity, increasing vulnerability to cerebral edema. Prevention requires the use of isotonic fluids for post-operative intravenous maintenance and avoidance of hypotonic solutions such as dextrose 5 percent in water or half-normal saline unless specifically indicated by the clinical situation.

Thiazide-Induced Hyponatremia

Thiazide diuretics are a common cause of clinically significant hyponatremia, most frequently affecting elderly women, typically within 1 to 2 weeks of drug initiation. The mechanism involves impairment of urinary diluting capacity through blockade of sodium chloride reabsorption in the distal convoluted tubule, the segment where urine is diluted, combined with enhanced water intake driven by thirst. Crucially, thiazides do not impair the urine concentrating mechanism because they do not affect the medullary thick ascending limb or disrupt the medullary concentration gradient, allowing ADH-mediated water reabsorption to proceed unopposed. This fundamental pharmacologic distinction explains why thiazides, unlike loop diuretics, are potent causes of hyponatremia. Loop diuretics, by impairing both diluting and concentrating ability through washout of the medullary gradient, rarely cause significant hyponatremia and are in fact used therapeutically to treat hyponatremia in SIADH by enhancing free water excretion. Treatment of thiazide-induced hyponatremia requires discontinuation of the thiazide, with careful correction of sodium. Recurrence is common if the thiazide is restarted.

Key Clinical Pearls

• Overcorrection is more dangerous than undercorrection in chronic hyponatremia; limit correction to <=8 mEq/L in 24 hours (<=6 in high-risk patients); always have a rescue plan with DDAVP and D5W
• The desmopressin clamp strategy is a powerful tool: proactively administer DDAVP to prevent unpredictable aquaresis (especially in hypovolemic hyponatremia or after glucocorticoid replacement), then raise sodium in a controlled manner with 3% NaCl
• Volume resuscitation of hypovolemic hyponatremia carries the highest risk of overcorrection: restoring EABV suppresses ADH leading to massive free water excretion and rapid sodium rise
• Urine electrolytes predict response to fluid restriction in SIADH: if UNa + UK > PNa, the kidney is generating electrolyte-free water-negative urine, and fluid restriction alone will not correct hyponatremia
• Thiazide diuretics cause hyponatremia by impairing urinary dilution; loop diuretics rarely cause hyponatremia and are actually used to TREAT hyponatremia in SIADH (enhance free water excretion)

References

1. Sterns RH. Disorders of Plasma Sodium — Causes, Consequences, and Correction. N Engl J Med. 2015;372(1):55-65.
2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations. Am J Med. 2013;126(10 Suppl 1):S1-S42.
3. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia (SALT-1 and SALT-2). N Engl J Med. 2006;355(20):2099-2112.
4. Sterns RH, Nigwekar SU, Hix JK. The Treatment of Hyponatremia. Semin Nephrol. 2009;29(3):282-299.
5. Soupart A, Penninckx R, Crenier L, et al. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int. 1994;45(1):193-200.

Read this lecture as Markdown